Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997-1998

被引:23
作者
Hellenbrand, W
Thierfelder, W
Müller-Pebody, B
Hamouda, O
Breuer, T
机构
[1] Robert Koch Inst, Dept Infect Dis Epidemiol, D-35133 Berlin, Germany
[2] Robert Koch Inst, Dept Epidemiol & Hlth Reporting, D-35133 Berlin, Germany
[3] Statens Serum Inst, Ctr Antimicrobial Resistance & Hosp Hyg, DK-2300 Copenhagen, Denmark
[4] GlaxoSmithKline Biol, B-1330 Rixensart, Belgium
关键词
D O I
10.1007/s10096-005-1286-x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to investigate the seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in representative samples of the total former East German (FEG) and total former West German (FWG) populations. Type-specific testing with the HSV-1 (gG1) and HSV-2 (gG2) indirect ELISA was performed on an age- and sex-stratified random subsample of 3,792 sera collected during the 1997-1998 German National Health Survey. Weighted seroprevalence estimates were calculated for the total FEG and FWG populations. The overall age-standardised seroprevalence of HSV-1 was 82.6% in Germany, 85.5% (95% CI, 83.4-87.3%) in FEG and 81.8% (95% CI, 79.9-83.6%) in FWG. The overall seroprevalence of HSV-2 was 13.3% (95% CI, 11.8-14.9) in Germany, 16.5% (95% CI, 14.1-18.9) in FEG and 12.6% (95% CI, 10.7-14.5%) in FWG. The difference between FEG and FWG was largely due to the significantly higher age-adjusted seroprevalence of HSV-1 and HSV-2 in women (but not men) in FEG as compared to FWG. The HSV seroprevalence estimates in this study are consistent with results of previous less representative seroprevalence studies in Germany. Differences in HSV-2 seroprevalence between FEG and FWG suggest differences in sexual behaviour that warrant further investigation.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 26 条
[1]  
Bahrdt B, 1992, Z HAUTKRANKHEITEN, V67, P56
[2]  
Bundeszentrale fur Gesundheitliche Aufklarung, 2002, JUG WIED 14 17 JAHR
[3]   Virology, epidemiology and diagnosis of genital herpes [J].
Chenot, JF ;
Rabenau, HF ;
Doerr, HW .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1999, 124 (06) :158-162
[4]  
COREY L, 1994, SEX TRANSM DIS S2, V21, P38
[5]   Seroprevalence study of herpes simplex virus type 2 among pregnant women in Germany using a type-specific enzyme immunoassay [J].
Enders, G ;
Risse, B ;
Zauke, M ;
Bolley, I ;
Knotek, F .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (12) :870-872
[6]   A monoclonal blocking EIA for herpes simplex virus type 2 antibody: validation for seroepidemiological studies in Africa [J].
Gopal, R ;
Gibbs, T ;
Slomka, MJ ;
Whitworth, J ;
Carpenter, LM ;
Vyse, A ;
Brown, DWG .
JOURNAL OF VIROLOGICAL METHODS, 2000, 87 (1-2) :71-80
[7]   A prospective study of new infections with herpes simplex virus type 1 and type 2 [J].
Langenberg, AGM ;
Corey, L ;
Ashley, RL ;
Leong, WP ;
Straus, SE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (19) :1432-1438
[8]   First episodes of genital herpes in a Swedish STD population:: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology [J].
Löwhagen, GB ;
Tunbäck, P ;
Andersson, K ;
Bergström, T ;
Johannisson, G .
SEXUALLY TRANSMITTED INFECTIONS, 2000, 76 (03) :179-182
[9]   RISK-FACTORS FOR THE SEXUAL TRANSMISSION OF GENITAL HERPES [J].
MERTZ, GJ ;
BENEDETTI, J ;
ASHLEY, R ;
SELKE, SA ;
COREY, L .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (03) :197-202
[10]  
Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19